HK1177739A1 - 2-arylimidazole derivatives as pde10a enzyme inhibitors pde10a 2- - Google Patents

2-arylimidazole derivatives as pde10a enzyme inhibitors pde10a 2-

Info

Publication number
HK1177739A1
HK1177739A1 HK13104851.5A HK13104851A HK1177739A1 HK 1177739 A1 HK1177739 A1 HK 1177739A1 HK 13104851 A HK13104851 A HK 13104851A HK 1177739 A1 HK1177739 A1 HK 1177739A1
Authority
HK
Hong Kong
Prior art keywords
pde10a
enzyme inhibitors
arylimidazole derivatives
arylimidazole
derivatives
Prior art date
Application number
HK13104851.5A
Other languages
English (en)
Chinese (zh)
Inventor
Ask Pschl
Jacob Nielsen
Jan Kehler
John Paul Kilburn
Mauro Marigo
Morten Langgrd
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of HK1177739A1 publication Critical patent/HK1177739A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK13104851.5A 2009-12-17 2013-04-22 2-arylimidazole derivatives as pde10a enzyme inhibitors pde10a 2- HK1177739A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200901341 2009-12-17
PCT/DK2010/050343 WO2011072696A1 (en) 2009-12-17 2010-12-15 2-arylimidazole derivatives as pde10a enzyme inhibitors

Publications (1)

Publication Number Publication Date
HK1177739A1 true HK1177739A1 (en) 2013-08-30

Family

ID=44246810

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13104851.5A HK1177739A1 (en) 2009-12-17 2013-04-22 2-arylimidazole derivatives as pde10a enzyme inhibitors pde10a 2-

Country Status (34)

Country Link
US (2) US8501797B2 (ru)
EP (1) EP2513105B1 (ru)
JP (1) JP5698761B2 (ru)
KR (1) KR101777889B1 (ru)
CN (1) CN102753551B (ru)
AR (1) AR079498A1 (ru)
AU (1) AU2010333437B2 (ru)
CA (1) CA2783727C (ru)
CO (1) CO6612246A2 (ru)
CR (1) CR20120317A (ru)
CY (1) CY1115278T1 (ru)
DK (1) DK2513105T3 (ru)
DO (1) DOP2012000168A (ru)
EA (1) EA021415B1 (ru)
ES (1) ES2484692T3 (ru)
GE (1) GEP20156242B (ru)
GT (1) GT201200180A (ru)
HK (1) HK1177739A1 (ru)
HR (1) HRP20140632T1 (ru)
MA (1) MA33924B1 (ru)
MX (1) MX2012007144A (ru)
MY (1) MY158202A (ru)
NZ (1) NZ600416A (ru)
PL (1) PL2513105T3 (ru)
PT (1) PT2513105E (ru)
RS (1) RS53413B (ru)
SG (1) SG181536A1 (ru)
SI (1) SI2513105T1 (ru)
SM (1) SMT201400114B (ru)
TN (1) TN2012000287A1 (ru)
TW (1) TWI481607B (ru)
UA (1) UA107817C2 (ru)
WO (1) WO2011072696A1 (ru)
ZA (1) ZA201204418B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI485151B (zh) * 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
TWI487705B (zh) 2009-12-17 2015-06-11 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
JO3089B1 (ar) * 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
EA025568B1 (ru) 2010-12-17 2017-01-30 Рита Фармасьютикалз, Инк. Пиразолильные и пиримидинильные трициклические еноны в качестве антиоксидантных модуляторов воспаления
KR20190022903A (ko) 2010-12-17 2019-03-06 노파르티스 아게 5-클로로-ｎ2-(2-이소프로폭시-5-메틸-4-피페리딘-4-일-페닐)-ｎ4[2-(프로판-2-술포닐)-페닐]-피리미딘-2,4-디아민의 결정질 형태
US8765760B2 (en) 2011-01-11 2014-07-01 Sunovion Pharmaceuticals, Inc. [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases
BR112013021180A2 (pt) 2011-02-18 2019-09-24 Allergan Inc derivados de 6,7-dialcóxi-3-isoquinolinol substituído como inibidores de fosfodiesterase 10 (pde10a)
US9938269B2 (en) * 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
AU2012299080B2 (en) * 2011-08-25 2016-03-17 Merck Sharp & Dohme Llc Pyrimidine PDE10 inhibitors
AR089361A1 (es) 2011-12-21 2014-08-20 Lundbeck & Co As H Derivados de quinolina como inhibidores de la enzima pde10a
WO2013107856A1 (en) * 2012-01-20 2013-07-25 H. Lundbeck A/S Imidazole derivatives as pde10a enzyme inhibitors
WO2013127817A1 (en) 2012-02-27 2013-09-06 H. Lundbeck A/S Imidazole derivatives as pde10a enzyme inhibitors
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
CN109923116B (zh) * 2016-11-02 2022-12-06 詹森药业有限公司 作为pde2抑制剂的[1,2,4]三唑并[1,5-a]嘧啶衍生物
GB202002926D0 (en) * 2020-02-28 2020-04-15 Benevolentai Tech Limited Compositions and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8307865D0 (en) 1983-03-22 1983-04-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives
US5571775A (en) 1994-07-11 1996-11-05 Dowelanco N-aryl[1,2,4]triazolo[1,5-a]pyridine-2-sulfonamide herbicides
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
IL149106A0 (en) 2001-04-20 2002-11-10 Pfizer Prod Inc Therapeutic use of selective pde10 inhibitors
FR2824065A1 (fr) 2001-04-26 2002-10-31 Neuro3D Composes inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations
KR20050033070A (ko) * 2002-08-09 2005-04-08 아스트라제네카 에이비이 메타보트로픽 글루타메이트 수용체-5의 조절제로서[1,2,4]옥사디아졸
AU2003288352A1 (en) 2002-10-30 2004-06-07 Centre National De La Recherche Scientifique (Cnrs) Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses
ES2331519T3 (es) 2003-06-30 2010-01-07 Nycomed Gmbh Derivados de pirrolo-dihidroisoquinolina como inhibidores de pde10.
NZ544591A (en) 2003-06-30 2009-07-31 Altana Pharma Ag Pyrrolodihydroisoquinolines as PDE10 inhibitors
CA2534432A1 (en) 2003-07-31 2005-02-10 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
WO2005014588A1 (en) 2003-08-01 2005-02-17 Argenta Discovery Limited Substituted thienyl-hydroxamic acids having histone deacetylase activity
EP1723134A2 (en) 2004-02-18 2006-11-22 Pfizer Products Incorporated Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline
FR2870539B1 (fr) 2004-05-19 2006-08-04 Greenpharma Sa Sa Nouvelles methodes et medicaments
CA2568929A1 (en) 2004-06-07 2005-12-22 Pfizer Products Inc. Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions
US20060019975A1 (en) 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
AU2005282721A1 (en) 2004-09-03 2006-03-16 Memory Pharmaceuticals Corporation 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms
CA2650976A1 (en) * 2006-05-02 2007-11-15 Pfizer Products Inc. Bicyclic heteroaryl compounds as pde10 inhibitors
US20080090834A1 (en) * 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
US8492394B2 (en) * 2006-07-10 2013-07-23 H. Lundbeck A/S (3-aryl-piperazin-1-yl), (2-aryl-morpholin-4-yl) and (2-aryl-thiomorpholin-4-yl) derivatives of 6,7-dialkoxy-quinazoline, 6,7-dialkoxyphtalazine and 6,7-dialkoxyisoquinoline as PDE10A enzyme inhibitors
JP2010533715A (ja) 2007-07-17 2010-10-28 アムジエン・インコーポレーテツド 複素環系ｐｋｂ調節剤
TWI501965B (zh) * 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
TWI487705B (zh) * 2009-12-17 2015-06-11 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物
TWI485151B (zh) * 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物

Also Published As

Publication number Publication date
GEP20156242B (en) 2015-02-10
DOP2012000168A (es) 2012-11-30
AU2010333437A1 (en) 2012-06-21
GT201200180A (es) 2015-01-16
TW201127831A (en) 2011-08-16
JP5698761B2 (ja) 2015-04-08
EP2513105B1 (en) 2014-05-14
PT2513105E (pt) 2014-07-31
US20130289038A1 (en) 2013-10-31
CN102753551B (zh) 2014-10-22
CA2783727A1 (en) 2011-06-23
ZA201204418B (en) 2013-08-28
MY158202A (en) 2016-09-15
JP2013514285A (ja) 2013-04-25
US20120302548A1 (en) 2012-11-29
RS53413B (en) 2014-12-31
SI2513105T1 (sl) 2014-11-28
MA33924B1 (fr) 2013-01-02
UA107817C2 (en) 2015-02-25
SMT201400114B (it) 2014-11-10
US8501797B2 (en) 2013-08-06
EP2513105A1 (en) 2012-10-24
AU2010333437B2 (en) 2016-09-01
SG181536A1 (en) 2012-07-30
PL2513105T3 (pl) 2014-09-30
EA021415B1 (ru) 2015-06-30
CA2783727C (en) 2018-02-20
CO6612246A2 (es) 2013-02-01
KR20120123276A (ko) 2012-11-08
EA201290518A1 (ru) 2013-01-30
HRP20140632T1 (hr) 2014-09-26
DK2513105T3 (da) 2014-07-14
CY1115278T1 (el) 2017-01-04
WO2011072696A1 (en) 2011-06-23
MX2012007144A (es) 2012-07-03
NZ600416A (en) 2013-08-30
TWI481607B (zh) 2015-04-21
ES2484692T3 (es) 2014-08-12
CN102753551A (zh) 2012-10-24
KR101777889B1 (ko) 2017-09-12
TN2012000287A1 (en) 2013-12-12
US8927738B2 (en) 2015-01-06
AR079498A1 (es) 2012-02-01
CR20120317A (es) 2012-08-16

Similar Documents

Publication Publication Date Title
HK1177739A1 (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors pde10a 2-
IL209834A (en) Phenylimidazole derivatives as a10pde enzyme sequences
GB201004179D0 (en) Enzyme inhibitors
GB201004178D0 (en) Enzyme inhibitors
ZA201109271B (en) Novel phenylimidazole derivative as pde10a enzyme inhibitor
HK1177208A1 (en) Heteroaromatic phenylimidazole derivatives as pde10a enzyme inhibitors pde10a
AP3342A (en) Imidazole derivatives as PDE10A enzyme inhibitors
HK1177745A1 (en) Heteroaromatic aryl triazole derivatives as pde10a enzyme inhibitors pde10a
GB0817429D0 (en) Enzyme inhibitors
HK1189593A1 (en) Imidazole derivatives as pde10a enzyme inhibitors pde10a
HK1171446A1 (en) Phenylimidazole derivative as pde10a enzyme inhibitor pde10a
GB0908068D0 (en) Enzyme inhibitors
GB0901616D0 (en) Enzyme inhibitors
GB0812443D0 (en) Enzyme inhibitors
GB0807056D0 (en) Enzyme inhibitors
GB0904936D0 (en) Enzyme inhibitor
GB0911102D0 (en) Enzyme inhibitor

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20211212